Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7987955 | 1.00 | CYP1A2 (0.53) | CYP1A2FBP1HDAC3ADAM17HDAC1 | |
| SCHEMBL7806244 | 1.00 | CYP1A2 (0.53) | CYP1A2FBP1HDAC3ADAM17HDAC1 | |
| SCHEMBL7799651 | 1.00 | CYP1A2 (0.53) | CYP1A2FBP1HDAC3ADAM17HDAC1 | |
| SCHEMBL7806247 | 1.00 | CYP1A2 (0.53) | CYP1A2FBP1HDAC3ADAM17HDAC1 | |
| SCHEMBL1224353 | 0.92 | CYP1A2 (0.57) | CYP1A2FBP1HDAC3ADAM17HDAC1 | |
| SCHEMBL1922783 | 0.92 | CYP1A2 (0.57) | CYP1A2FBP1HDAC3ADAM17HDAC1 | |
| SCHEMBL28777799 | 0.87 | CYP1A2 (0.55) | CYP1A2FBP1HDAC3ADAM17HDAC1 | |
| SCHEMBL9970464 | 0.87 | CYP1A2 (0.59) | CYP1A2FBP1HDAC3ADAM17HDAC1 | |
| SCHEMBL6418950 | 0.82 | MAOB (0.58) | CYP1A2FBP1HDAC3ADAM17HDAC1 | |
| SCHEMBL7609956 | 0.79 | CYP1A1 (0.59) | CYP1A2FBP1HDAC3ADAM17HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6306880-B1 | HETEROCYCLIC ALCOHOL DERIVATIVES AS FUNGICIDES | SANKYO COMPANY, LIMITED (JP) | 2001-10-23 | — | — | US | disclosed |
| US-20010031778-A1 | Triazole antifungal agent | SANKYO COMPANY LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
| US-20010031768-A1 | Triazole antifungal agent | SANKYO COMPANY LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
| US-6300357-B1 | FOR THERAPY OF MYCOTIC DISEASE OF A HUMAN BEING AND AN ANIMAL | SANKYO COMPANY, LIMITED (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-0841327-B1 | TRIAZOLE ANTIFUNGAL AGENT | SANKYO CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-5977152-A | Triazole antifungal agent | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0841327-A1 | TRIAZOLE ANTIFUNGAL AGENT | SANKYO COMPANY LIMITED (JP) | 1998-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031768-A1 | Triazole antifungal agent | ERG28, RIF1, NAT1 | CYP1A2 21/4885FBP1 1923/4885HDAC3 29/4885 |
| US-20010031778-A1 | Triazole antifungal agent | ERG28, NAT1, RIF1 | CYP1A2 151/4885FBP1 1079/4885HDAC3 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.